Calcimedica, INC 10-Q quarterly reports

CalciMedica, Inc. announced its first quarter 2026 financial results, reporting a net income of $5.0 million, a significant turnaround from the prior year's net loss.

CalciMedica, a clinical-stage biopharmaceutical company, reported increased net losses and expressed substantial doubt about its ability to continue as a going concern, despite securing new debt financing and expanding its ATM facility.

CalciMedica, a clinical-stage biopharmaceutical company, reported increased net losses and a 'substantial doubt' about its ability to continue as a going concern, despite ongoing clinical trial progress for its lead candidate, Auxora.

CalciMedica, a clinical-stage biopharmaceutical company, announces its financial results for the first quarter of 2025, highlighting ongoing clinical trials and financial activities.

CalciMedica's Q3 2024 report details financial results and provides updates on clinical trials, including the ongoing Phase 2 trial for Auxora in acute kidney injury.

CalciMedica's Q2 2024 report shows a net loss of $3.8 million, offset by gains in fair value of financial instruments and a private placement, as the company advances its clinical programs.

CalciMedica reports a net income of $0.1 million for the first quarter of 2024, driven by a gain from fair value adjustments to warrant liabilities, while also highlighting ongoing clinical trial advancements.